{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:53:42Z","timestamp":1790517222169,"version":"4.1.0"},"reference-count":27,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2006,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            MenBvac is an outer membrane vesicle vaccine against systemic meningococcal disease caused by serogroup B\n            <jats:italic>Neisseria meningitidis<\/jats:italic>\n            . In this placebo-controlled double-blind study including 374 healthy adolescents, the safety and immunogenicity of a schedule of three primary doses 6 weeks apart followed by a fourth dose a year later were evaluated. Antibody responses to the vaccine strain and heterologous strains (non-vaccine-type strains) and the persistence of these antibodies were measured by the serum bactericidal assay (SBA) and enzyme-linked immunosorbent assay up to 1 year after the last dose. The proportion of subjects with SBA titers of \u22654 against the vaccine strain increased from 3% prevaccination to 65% after the third dose. Ten months later, this proportion had declined to 28%. The fourth dose induced a booster response demonstrated by 93% of subjects achieving a titer of \u22654. One year after the booster dose, 64% still showed SBA titers of \u22654. Cross-reacting antibodies were induced against all heterologous strains tested, although the magnitude of SBA titers differed widely between the different strains. All four doses of MenBvac were safe. Both MenBvac and the placebo had reactogenicity profiles of mild to moderate local and systemic reactions. Pain, the most common reaction, was reported with similar frequencies in both groups. No serious adverse events occurred in the MenBvac group. This study confirmed the good immunogenicity of the primary course of MenBvac and demonstrated prolonged persistence and increased cross-reactivity of functional antibodies elicited by a booster dose.\n          <\/jats:p>","DOI":"10.1128\/cvi.00047-06","type":"journal-article","created":{"date-parts":[[2006,7,7]],"date-time":"2006-07-07T19:12:52Z","timestamp":1152299572000},"page":"790-796","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":37,"title":["Persisting Immune Responses Indicating Long-Term Protection after Booster Dose with Meningococcal Group B Outer Membrane Vesicle Vaccine"],"prefix":"10.1128","volume":"13","author":[{"given":"Berit","family":"Feiring","sequence":"first","affiliation":[{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway"},{"name":"Chiron Srl, Siena, Italy"},{"name":"Chiron B.V., Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Fuglesang","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway"},{"name":"Chiron Srl, Siena, Italy"},{"name":"Chiron B.V., Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Oster","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway"},{"name":"Chiron Srl, Siena, Italy"},{"name":"Chiron B.V., Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisbeth M.","family":"N\u00e6ss","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway"},{"name":"Chiron Srl, Siena, Italy"},{"name":"Chiron B.V., Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oddveig S.","family":"Helland","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway"},{"name":"Chiron Srl, Siena, Italy"},{"name":"Chiron B.V., Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Tilman","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway"},{"name":"Chiron Srl, Siena, Italy"},{"name":"Chiron B.V., Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar","family":"Rosenqvist","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway"},{"name":"Chiron Srl, Siena, Italy"},{"name":"Chiron B.V., Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne A. R.","family":"Bergsaker","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway"},{"name":"Chiron Srl, Siena, Italy"},{"name":"Chiron B.V., Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne","family":"N\u00f8kleby","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway"},{"name":"Chiron Srl, Siena, Italy"},{"name":"Chiron B.V., Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingeborg S.","family":"Aaberge","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway"},{"name":"Chiron Srl, Siena, Italy"},{"name":"Chiron B.V., Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1128\/CDLI.12.5.599-605.2005","volume":"12","year":"2005","unstructured":"Aaberge, I. S., P. Oster, O. S. Helland, A.-C. Kristoffersen, E. Ypma, E. A. H\u00f8iby, B. Feiring, and H. N\u00f8kleby. 2005. Combined administration of meningococcal serogroup B outer membrane vesicle vaccine and conjugated serogroup C vaccine indicated for prevention of meningococcal disease is safe and immunogenic. Clin. Diagn. Lab. Immunol.12:599-605.","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1046\/j.1440-1754.2001.00722.x","volume":"37","year":"2001","unstructured":"Baker, M. G., D. R. Martin, C. E. Kieft, and D. Lennon. 2001. A 10-year serogroup B meningococcal disease epidemic in New Zealand: descriptive epidemiology, 1991-2000. J. Paediatr. Child Health37:S13-S19.","journal-title":"J. Paediatr. Child Health"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/0140-6736(91)91961-S","volume":"338","year":"1991","unstructured":"Bjune, G., E. A. H\u00f8iby, J. K. Gr\u00f8nnesby, O. Arnesen, J. H. Fredriksen, A. Halstensen, E. Holten, A. K. Lindbak, H. N\u00f8kleby, E. Rosenqvist, L. K. Solberg, O. Closs, J. Eng, L. Froholm, A. Lystad, L. Bakketein, and B. Hareide. 1991. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet338:1093-1096.","journal-title":"Lancet"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","volume":"23","year":"2005","unstructured":"Borrow, R., P. Balmer, and E. Miller. 2005. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine23:2222-2227.","journal-title":"Vaccine"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1128\/CDLI.12.8.970-976.2005","volume":"12","year":"2005","unstructured":"Borrow, R., I. S. Aaberge, G. F. Santos, T. L. Eudey, P. Oster, A. Glennie, J. Findlow, E. A. H\u00f8iby, E. Rosenqvist, P. Balmer, and D. Martin. 2005. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup B, strain 44\/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin. Diagn. Lab. Immunol.12:970-976.","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1699-0463.1998.tb01379.x","volume":"106","year":"1998","unstructured":"Caugant, D. A. 1998. Population genetics and molecular epidemiology of Neisseria meningitidis. APMIS106:505-525.","journal-title":"APMIS"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1017\/S0950268800047713","volume":"105","year":"1990","unstructured":"Cruz, C., G. Pavez, E. Aguilar, L. Grawe, J. Cam, F. Mendez, J. Garcia, S. Ruiz, P. Vicent, and I. Canepa. 1990. Serotype-specific outbreak of group B meningococcal disease in Iquique, Chile. Epdemiol. Infect.105:119-126.","journal-title":"Epdemiol. Infect."},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/0140-6736(92)93086-3","volume":"340","year":"1992","unstructured":"de Moraes, J. C., B. A. Perkins, M. C. Camargo, N. T. Hidalgo, H. A. Barbosa, C. T. Sacchi, I. M. Landgraf, V. L. Gattas, and H. de G. Vasconcelos. 1992. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet340:1074-1078.","journal-title":"Lancet"},{"key":"e_1_3_2_10_2","unstructured":"EU-IBIS. 29 May 2006 last date modified. Neisseria meningitidis network (in collaboration with EU-MenNet). [Online.] http:\/\/www.euibis.org\/neisseria.htm\n. Accessed 16 November 2005."},{"key":"e_1_3_2_11_2","first-page":"67","volume":"14","year":"1991","unstructured":"Fredriksen, J. H., E. Rosenqvist, E. Wedege, K. Bryn, G. Bjune, L. O. Fr\u00f8holm A. K. Lindbak, B. Mogster, E. Namork, and U. Rye. 1991. Production, characterization and control of MenB-vaccine \u201cFolkehelsa\u201d: an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann.14:67-79.","journal-title":"NIPH Ann."},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0264-410X(02)00591-1","volume":"21","year":"2003","unstructured":"Holst, J., B. Feiring, J. E. Fuglesang, E. A. H\u00f8iby, H. N\u00f8kleby, I. S. Aaberge, and E. Rosenqvist. 2003. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine21:734-737.","journal-title":"Vaccine"},{"key":"e_1_3_2_13_2","unstructured":"L\u00f8voll \u00d8. D. A. Caugant and L. O. Fr\u00f8holm. 2002. MSIS report. Meldingssystem for smittsomme sykdommer. (Weekly newsletter of the Norwegian Institute of Public Health Oslo) 30 : 18."},{"key":"e_1_3_2_14_2","first-page":"57","volume":"14","year":"1991","unstructured":"Lystad, A., and S. Aasen. 1991. The epidemiology of meningococcal disease in Norway 1975-91. NIPH Ann.14:57-66.","journal-title":"NIPH Ann."},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1086\/517385","volume":"177","year":"1998","unstructured":"Martin, D. R., S. J. Walker, M. G. Baker, and D. R. Lennon. 1998. New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4. J. Infect. Dis.177:497-500.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/S0264-410X(00)00324-8","volume":"19","year":"2001","unstructured":"Michaelsen, T. E., A. Aase, J. Kolberg, E. Wedege, and E. Rosenqvist. 2001. PorB3 outer membrane protein on Neisseria meningitidis is poorly accessible for antibody binding on live bacteria. Vaccine19:1526-1533.","journal-title":"Vaccine"},{"key":"e_1_3_2_17_2","first-page":"666","volume":"20","year":"2002","unstructured":"Morley, S. L., and A. J. Pollard. 2002. Vaccine prevention of meningococcal disease, coming soon? Vaccine20:666-687.","journal-title":"Vaccine"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0264-410X(98)00259-X","volume":"17","year":"1999","unstructured":"N\u00e6ss, L. M., T. Aarvak, A. Aase, F. Oftung, E. A. H\u00f8iby, R. Sandin, and T. E. Michaelsen. 1999. Human IgG subclass response in relation to serum bactericidal and opsonic activities after immunization with three doses of the Norwegian serogroup B meningococcal outer membrane vesicle vaccine. Vaccine17:754-764.","journal-title":"Vaccine"},{"key":"e_1_3_2_19_2","first-page":"95","volume":"14","year":"1991","unstructured":"N\u00f8kleby, H., and B. Feiring. 1991. The Norwegian meningococcal group B outer membrane vesicle vaccine: side effects in phase II trials. NIPH Ann.14:95-102.","journal-title":"NIPH Ann."},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.vaccine.2005.01.063","volume":"23","year":"2005","unstructured":"Oster, P., D. Lennon, J. O\u2019Hallahan, K. Mulholland, S. Reid, and D. Martin. 2005. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine23:2191-2196.","journal-title":"Vaccine"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1086\/514232","volume":"177","year":"1998","unstructured":"Perkins, B. A., K. Jonsdottir, H. Briem, E. Griffiths, B. D. Plikaytis, E. A. H\u00f8iby, E. Rosenqvist, J. Holst, H. N\u00f8kleby, F. Sotolongo, G. Sierra, H. C. Campa, G. M. Carlone, D. Williams, J. Dykes, D. Kapczynski, E. Tikhomirov, J. D. Wenger, and C. V. Broome. 1998. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J. Infect. Dis.177:683-691.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.26.8.1543-1548.1988"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.63.12.4642-4652.1995"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.30.7.1734-1738.1992"},{"key":"e_1_3_2_25_2","first-page":"195","volume":"14","year":"1991","unstructured":"Sierra, G. V., H. C. Campa, N. M. Varcacel, I. L. Garcia, P. L. Izquierdo, P. F. Sotolongo, G. V. Casanueva, C. O. Rico, C. R. Rodriguez, and M. H. Terry. 1991. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann.14:195-207.","journal-title":"NIPH Ann."},{"key":"e_1_3_2_26_2","first-page":"1520","volume":"281","year":"1999","unstructured":"Tappero, J. W., R. Lagos, A. M. Ballesteros, B. Plikaytis, D. Williams, J. Dykes, L. L. Gheesling, G. M. Carlone, E. A. H\u00f8iby, J. Holst, H. N\u00f8kleby, E. Rosenqvist, G. Sierra, C. Campa, F. Sotolongo, J. Vega, J. Garcia, P. Herrera, J. T. Poolman, and B. A. Perkins. 1999. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines. A randomized controlled trial in Chile. JAMA281:1520-1527.","journal-title":"JAMA"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.66.7.3223-3231.1998"},{"key":"e_1_3_2_28_2","first-page":"514","volume":"136","year":"1972","unstructured":"Wyle, F. A., M. S. Artenstein, B. L. Brandt, E. C. Tramont, D. L. Kasper, P. L. Altieri, S. L. Berman, and J. P. Lowenthal. 1972. Immunological response of man to group B meningococcal polysaccharide vaccines. J. Infect. Dis.136:514-522.","journal-title":"J. Infect. Dis."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00047-06","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00047-06","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:37:10Z","timestamp":1627591030000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00047-06"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["10.1128\/CVI.00047-06"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00047-06","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7]]},"assertion":[{"value":"2006-02-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2006-04-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}